NEW YORK, July 24, 2017 /PRNewswire/ -- The litigation involving Risperdal and gynecomastia continues to grow, with more than 5,500 cases now pending in the mass tort program currently underway in the Philadelphia Court of Common Pleas. According to The Legal Intelligencer, the number of Pennsylvania Risperdal lawsuit filings have doubled since the beginning of the year, and the docket now makes up more than 55% of the Philadelphia Complex Litigation Center's case inventory. (Case No. 130600861)
"Our Firm continues to receive inquiries from Risperdal users who claim to have experienced excessive male breast growth as a result of this drug. We are not surprised to see such a sharp increase in the Pennsylvania mass tort program," said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide free legal reviews to men and boys who were diagnosed with gynecomastia allegedly related to their use of Risperdal.
Risperdal and Gynecomastia
Risperdal is an atypical antipsychotic medication indicated for use in adult and adolescent patients with schizophrenia, adults and children ages 10-to-17 with bipolar disorder, and children (5-to-16 years of age) with autistic disorder. Johnson & Johnson and its Janssen Pharmaceuticals unit are accused of failing to warn doctors and patients about the potential for Risperdal to cause excessive male breast growth. It is also alleged that Johnson & Johnson and Janssen wrongly marketed Risperdal to treat children long before the U.S. Food & Drug Administration approved the medication for pediatric use in 2006.
The Pennsylvania litigation has convened eight Risperdal gynecomastia trials since early 2015. Four of those plaintiffs have been awarded damages ranging from $500,000 to $70 million. Confidential Risperdal settlements have also been reported in other cases just prior to trial.
Bernstein Liebhard LLP continues to provide free legal reviews to alleged victims of Risperdal and gynecomastia. To learn more about filing a Risperdal lawsuit, please contact Bernstein Liebhard LLP by visiting the Firm's website, or by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP